This page collects WhisperX intelligence signals tagged #Biotech Finance. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
MeiraGTx Holdings plc has filed a significant 8-K form with the SEC, revealing multiple material developments in a single disclosure. The filing, submitted on March 26, 2026, indicates the company has entered into a new definitive agreement and has created a direct financial obligation, signaling active financial and o...
Denali Therapeutics Inc. has filed an 8-K form with the SEC, disclosing the creation of a new direct financial obligation or an off-balance sheet arrangement. The filing, submitted on March 31, 2026, signals a material change in the company's financial structure, though the specific terms, counterparties, and monetary ...
ImmunityBio, Inc. has filed a significant 8-K form with the SEC, signaling a series of critical corporate developments. The filing, submitted on March 31, 2026, includes disclosures under multiple material items, most notably the creation of a new direct financial obligation and the entry into a material definitive agr...
Entera Bio Ltd. has filed a significant 8-K form with the SEC, disclosing a material definitive agreement and an unregistered sale of equity securities. The filing, submitted on April 3, 2026, signals a pivotal corporate transaction that could reshape the company's financial structure and strategic direction. The inclu...
Transcode Therapeutics, Inc. has filed a multi-faceted 8-K with the SEC, signaling significant corporate and financial activity. The filing, submitted on April 7, 2026, discloses the company's entry into a material definitive agreement, the creation of a direct financial obligation, and an unregistered sale of equity s...
ImageneBio, Inc. has filed a significant 8-K form with the SEC, disclosing two critical corporate actions that point to a major operational or financial development. The filing, submitted on April 13, 2026, formally notes the company's entry into a "Material Definitive Agreement" and the execution of an "Unregistered S...
Enveric Biosciences has triggered a significant SEC disclosure, filing an 8-K form that flags multiple material corporate events. The filing, submitted on April 20, 2026, includes entries for entering into a material definitive agreement, conducting an unregistered sale of equity securities, and reporting other unspeci...
Damora Therapeutics, Inc. has abruptly changed its independent registered public accounting firm, a move disclosed in a formal 8-K filing with the SEC. The filing, submitted on April 20, 2026, indicates a significant shift in the company's financial oversight, triggering immediate regulatory scrutiny. Such a change, pa...
NKGen Biotech has filed a dense 8-K with the SEC, disclosing a multi-pronged corporate restructuring in a single filing. The company has entered into a material definitive agreement, created a direct financial obligation, conducted an unregistered sale of equity securities, and amended its articles of incorporation or ...